10-K/A: Cyclo Therapeutics Files Amended 10-K, Cites Merger and Clinical Progress

Cyclo Therapeutics files an amendment to its annual report, detailing a recent merger, clinical trial updates, and financial results for the year ended December 31, 2023.

Summary

• Cyclo Therapeutics, a clinical-stage biotechnology company, filed an amendment to its annual report on Form 10-K/A.
• The amendment addresses SEC comments on previous filings, specifically regarding clinical studies and financial discussions.
• The company is focused on developing cyclodextrin-based products, primarily for neurodegenerative diseases, with a lead drug candidate, Trappsol Cyclo, for Niemann-Pick Type C disease (NPC).
• A merger with Applied Molecular Transport, Inc. (AMTI) was completed on December 27, 2023, in an all-stock transaction.
• The company's Phase III clinical trial for Trappsol Cyclo in NPC is ongoing, with an interim analysis planned at 48 weeks.
• The company is also exploring the use of Trappsol Cyclo for Alzheimer's disease, with a Phase II study underway.
• The company's legacy fine chemical business continues, but the focus has shifted to biopharmaceutical development.
• For 2023, the company reported a net loss of approximately $20.06 million, compared to a net loss of approximately $15.45 million in 2022.
• Total revenues for 2023 were approximately $1.08 million, down from approximately $1.38 million in 2022.
• Research and development expenses increased to approximately $14.18 million in 2023, up from approximately $9 million in 2022.
• The company's cash increased to approximately $9.25 million as of December 31, 2023, compared to approximately $1.54 million as of December 31, 2022, primarily due to equity transactions and the merger.
• The company has a significant amount of net operating loss carryforwards, but has a full valuation allowance against its deferred tax assets.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is progress in clinical trials and a successful merger, the increasing losses and need for future capital raises temper the positive aspects. The auditor's going concern warning also contributes to a neutral to slightly negative sentiment.

Positives

• The merger with AMTI has significantly increased the company's cash position.
• The company has made progress in its clinical trials for both NPC and Alzheimer's disease.
• The company has received a notice of allowance for a patent application related to Alzheimer's disease treatment.
• The company has orphan drug designation for Trappsol Cyclo in both the US and Europe, providing market exclusivity upon approval.
• The company has a fast track designation from the FDA for Trappsol Cyclo for the treatment of NPC.
• The company has a rare pediatric disease designation from the FDA for NPC, which could lead to a priority review voucher.

Negatives

• The company experienced a net loss of approximately $20.06 million in 2023, an increase from $15.45 million in 2022.
• Total revenues decreased to approximately $1.08 million in 2023 from approximately $1.38 million in 2022.
• The company's reliance on a few major customers for its legacy fine chemical business creates revenue concentration risk.
• The company has a full valuation allowance on its deferred tax assets, indicating uncertainty about future profitability.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.
• The company will need to raise additional capital in the future to support its ongoing operations and clinical trials.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• The company's clinical trials may not be successful, and regulatory approvals may not be granted.
• The company faces competition in the development of treatments for NPC and Alzheimer's disease.
• The company's legacy fine chemical business is subject to fluctuations in customer demand and pricing pressures.
• The company's financial results are subject to fluctuations in currency exchange rates.
• The company is subject to risks associated with government regulation of biopharmaceutical products.
• The company is subject to risks associated with healthcare reform and changes in reimbursement policies.

Future Outlook

The company expects to continue to raise additional capital through the sale of its securities from time to time for the foreseeable future to fund the development of its drug product candidates through clinical development, manufacturing, and commercialization.

Management Comments

• Management believes that Trappsol Cyclo can function like the NPC1 protein, allowing cholesterol and other lipids to be moved normally through cells.
• Management believes that the company may be the only company with a drug candidate that treats both the systemic and neurological manifestations of NPC.
• Management believes that the company's clinical progress, close connections with patient advocacy groups, and the fact that it has a finished product currently in use in human patients give it a competitive advantage.
• Management believes that the company has established business relationships with many of the producers and consumers of cyclodextrins worldwide and, over more than 30 years, has developed an unmatched experience database.

Industry Context

The company is operating in the biotechnology sector, specifically focusing on rare diseases. The development of treatments for NPC and Alzheimer's disease is an area of significant unmet medical need. The company's use of cyclodextrins as an active pharmaceutical ingredient is a novel approach in the industry.

Comparison to Industry Standards

• The company's approach of using cyclodextrins as an active pharmaceutical ingredient is unique, as most companies use them as excipients.
• The company's clinical trial results for Trappsol Cyclo in NPC show promising efficacy signals, with improvements in multiple domains of the NPC Clinical Severity Scale.
• The company's Phase III trial is a pivotal study, which is a standard approach for seeking regulatory approval for a new drug.
• The company's research and development expenses are significant, reflecting the high cost of drug development in the biotechnology industry.
• The company's reliance on a few major customers for its legacy fine chemical business is a common risk for smaller companies in the chemical industry.
• The company's financial losses are typical for clinical-stage biotechnology companies that are investing heavily in research and development.

Management Changes

Legal Proceedings

• In December 2023, two lawsuits were filed against AMTI in connection with the Merger. The Company has accrued an estimate of potential liability based on the best information available. While the outcome remains uncertain, the Company does not expect the lawsuits to have a material adverse effect on cash flows, financial condition, or results of operations.

Related Party Transactions

• The company pays a monthly fee to C.E. Rick Strattan, a director, for consulting services.
• The company employs Joshua M. Fine, the son of the CEO, as Chief Financial Officer.
• The company employs Kevin J. Strattan, the son of C.E. Rick Strattan, as Vice President, Finance Compensation.
• The company employs Corey E. Strattan, the daughter-in-law of C.E. Rick Strattan, as a documentation specialist and logistics coordinator.
• Scott Fine, Chief Executive Officer and certain board members and affiliates purchased shares of common stock and warrants in a private placement on April 20, 2023.
• Scott Fine, Chief Executive Officer and certain board members and affiliates exercised warrants and in exchange were issued new warrants on October 20, 2023.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings.
• Employees are subject to the risks associated with the company's financial stability.
• Patients with NPC and Alzheimer's disease may benefit from the company's drug development efforts.
• Customers of the company's legacy fine chemical business are subject to the company's ability to maintain supply.
• Creditors are subject to the risks associated with the company's ability to repay its debts.

Next Steps

• The company will continue its Phase III clinical trial for Trappsol Cyclo in NPC, with an interim analysis planned at 48 weeks.
• The company will continue its Phase II study of Trappsol Cyclo for the treatment of Alzheimer's disease.
• The company will continue to pursue regulatory approvals for Trappsol Cyclo.
• The company will continue to raise additional capital to fund its operations and clinical trials.

Key Dates

Keywords

Cyclo Therapeutics, Trappsol Cyclo, Niemann-Pick Type C disease, Alzheimer's disease, clinical trials, biotechnology, orphan drug, merger, cyclodextrins, pharmaceuticals